The IRF1 Knockout RBE Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the RBE human cholangiocyte cell line, engineered to disrupt the expression of interferon regulatory factor 1 (IRF1). This heterogeneous gene-disrupted pool provides a versatile loss-of-function model for investigating IRF1-mediated transcriptional programs and signaling networks in a biliary epithelial context.
The RBE cell line is a well-characterized human intrahepatic cholangiocarcinoma model originally established from a patient with biliary tract cancer. These cholangiocyte-derived cells form epithelial monolayers and retain key features of the biliary epithelium, including bile secretory and modification functions. RBE cells are widely employed in preclinical research to dissect the molecular mechanisms underlying cholangiocarcinoma pathogenesis, metastasis, and therapeutic resistance.
IRF1 functions as a pivotal transcriptional regulator downstream of interferon and cytokine signaling pathways. Upon stimulation by IFN-??, TNF-??, or IL-1??, the IFN-?? receptor activates JAK1/JAK2 kinases, leading to STAT1 phosphorylation and nuclear translocation, where STAT1 directly promotes IRF1 transcription. IRF1 can also be activated through NF-??B and TLR3/TLR4 pathways. Once expressed, IRF1 binds to GAS elements and interferon-stimulated response elements to drive the expression of target genes such as OAS1, MX1, PKR, MHC class I molecules, caspase-1, caspase-8, p21/WAF1, Bak, IL-12, and CXCL10. IRF1 also interacts with STAT2, IRF2, NF-??B, and p53 to integrate signals controlling apoptosis, cell cycle arrest, and innate immune responses.
In the RBE cholangiocarcinoma background, IRF1 knockout likely abrogates interferon-induced antiproliferative and pro-apoptotic programs, thereby impairing tumor cell growth inhibition and immune surveillance. This model enables precise dissection of IRF1-dependent tumor-suppressive pathways, including the interplay between IRF1 and the p53 network, and permits evaluation of how loss of IRF1 alters sensitivity to cytokines and chemotherapeutic agents. Consequently, these cells serve as a powerful tool for exploring bile duct cancer vulnerabilities and immune evasion strategies.
Typical experimental applications include the study of interferon signaling dynamics in biliary tract cancers, investigation of immune checkpoint regulators, and functional genomics screening for novel therapeutic targets. Researchers can perform Western blotting and RT-qPCR to assess IRF1 downstream targets, flow cytometry-based apoptosis and cell cycle analyses, and interferon treatment assays to map signaling outputs. Migration/invasion and drug sensitivity assays further extend the utility of these knockout cells in translational oncology research. For detailed product specifications or technical support, please contact Ascent Research.
